Cambrex Completes HPAPI Manufacturing Facility

Published 4-27-2019

Cambrex Corporation completed construction in April of 2019 on a $24 million facility for the manufacture of highly potent active pharmaceutical ingredients (HPAPIs) in Charles City, Iowa. The 6,000-sf project houses four reactors with capacities ranging from 200 to 1,000 gallons to accommodate batches from 50 to 300 kilograms. An existing small scale manufacturing area has also been reconfigured. With the ability to operate to an occupational exposure limit (OEL) down to 0.1µg/m3, the high-containment facility can support product development and analysis across the entire drug lifecycle.